I concede that future funding was not stated in any of the correspondence. The initial issues was Merlin being late in its reporting in October, which lead to suspension. At the time it seemed that the main issue was the financial viability of Merlin because the Auditors comments did express doubt.
I think the suspension triggered a reaction from ASX where they wanted clarification on a few issues before discontinuing the suspension. The AXIS loan quickly became the dominant issue, as the responses from Merlin were unsatisfactory.
MED Price at posting:
0.6¢ Sentiment: Sell Disclosure: Held
